CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial...

MM Regan，LJ Brian，B Mark，... - 《J Natl Cancer Inst》

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial.

The author discusses a study by M. M. Regan et al on CYP2D6 genotype and tamoxifen response in postmenopausal women with breast cancer. He suggests the serious doubts about conclusions raised by the implausible CYP2DC6 genotyping results...

Stanton，Jr.，Vincent，... - 《Jnci Journal of the National Cancer Institute》

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast c...

Pharoah PD, Abraham J, Caldas C: Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of ...

Pharoah，DP P.，Abraham，... - 《Journal of the National Cancer Institute》

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and R...

A letter to the editor is presented in response to the articles on the association of CYP2D6 genotype with tamoxifen hormone therapy response in the 2012 i...

PD Pharoah，J Abraham，C Caldas - 《Jnci Journal of the National Cancer Institute》

Response

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J ...

MM Regan，M Bouzyk，JM Rae，... - 《Jnci J》

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

A. (2012). Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98...

M Meredith，Regan，Brian，... - 《Journal of the National Cancer Institute》

Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8.

14 Background : Historically, standard endocrine treatment for postmenopausal women with hormone-sensitive early breast cancer (EBC) was 5 years' tamoxifen. However, the inclusion of an aromatase inhibitor (AI) is now considered standard...

R Jakesz，M Gnant，R Griel，... - 《Cancer Research》

Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor

BACKGROUND: Controversy persists about whether chemotherapy benefits all breast cancer patients. PATIENTS AND METHODS: In the International Breast Cancer S...

Colleoni，M. - 《Annals of Oncology》